Wiskott-Aldrich Syndrome: A Family That Already Knows How This Ends Untreated
A fourteen-month-old boy with bloody stools and eczema carries the same diagnosis that killed his mother's brother before anyone had a name for it. The urgency is real — the argument is whether his platelet count makes today the wrong day to start conditioning.
Jonah P. is fourteen months old, and his parents already know, in a way most new diagnoses don't come with, roughly what happens if this goes untreated: his mother's younger brother died of an intracranial hemorrhage at age six, decades before anyone connected his lifelong eczema, bloody diarrhea, and easy bruising to a single X-linked gene. Jonah's own presentation — petechiae since infancy, a platelet count that has never cleared 30,000, bloody stools that brought him to urgent care twice in the past two months, and eczema across both cheeks and his scalp since three months of age — led to genetic confirmation of a pathogenic WAS variant three weeks ago. He has otherwise met every developmental milestone on schedule and has had only two ear infections in his life, both resolving normally with oral antibiotics.
His Zhu clinical severity score, which grades WAS from mild thrombocytopenia alone up through the classic full triad plus autoimmune or malignant complications, places him at a level where progression is expected without definitive therapy. Hacein-Bey Abina et al., 2015, JAMA, followed seven children with exactly this severity treated with lentiviral gene therapy — six survived with meaningful clinical improvement, eczema and autoimmune manifestations both reduced, though platelet reconstitution remained incomplete in several. What complicates today's decision isn't whether he needs definitive therapy — nobody on his team disputes that — it’s that his count has climbed only to 24,000 from the 11,000 it hit after his second bloody-stool episode two weeks ago. That is a recovering number, but it is still less than half the 50,000 that would give busulfan conditioning any hemorrhagic margin at all, and it was reached too recently to be called a trend rather than a rebound. His parents, having watched one family member's disease go unnamed until it was fatal, are the ones who keep asking whether any delay at all is the wrong call.
Urgent, but not on a bleeding platelet count
His Zhu score already puts him in the range where we expect progression, not stability, without definitive therapy. Hacein-Bey Abina and colleagues followed seven children at his severity treated with gene therapy — six survived with real clinical improvement. Outcomes in this disease are consistently better the earlier definitive therapy happens, before autoimmune and infectious complications start compounding. I want to move toward conditioning on the fastest safe timeline.
I don't disagree that he needs definitive therapy — nobody here does. What I don't think 'fastest' should mean is starting busulfan conditioning while his platelet count sits at 24,000, two weeks after it was 11,000 and he had a second bleeding episode. Conditioning itself adds marrow suppression on top of a baseline that already can't reliably form a clot.
Earlier is better as a general pattern across the published cohorts — it isn't better if 'earlier' means starting conditioning during an active bleeding episode rather than after it's actually resolved.
His family's own history is exactly why open-ended delay isn't a neutral option either — but that argues for a bounded stabilization window, not for skipping one. A short course of eltrombopag is what I’d use, and I want to be exact about what we’re borrowing, because its trial evidence is in immune-mediated thrombocytopenia and Jonah’s is not immune-mediated — his platelets are small and structurally abnormal because of the WAS defect itself. What transfers is the thrombopoietin-receptor drive on his megakaryocytes, not the response rates. So we treat the target, not the drug, as the thing we’re committing to: reliably above 50,000 for two consecutive weeks gives conditioning a real safety margin without turning this into an indefinite wait, and if eltrombopag doesn’t get him there we have learned that in weeks rather than assumed it. Set that number in advance, and conditioning proceeds the day he clears it — not later, and not sooner.
Eltrombopag was started with an explicit platelet target of 50,000 sustained for two consecutive weeks, at which point busulfan conditioning would proceed regardless of calendar time elapsed. He crossed that threshold nineteen days later without a further bleeding episode, and conditioning began on schedule the following week.
Agreed by all three, and treated as the case's actual resolution: setting an explicit physiologic threshold rather than either a fixed calendar delay or an immediate start date let both the urgency argument and the bleeding-risk argument be fully honored without either side conceding the underlying point.